| 1520 |
National Cancer Institute |
Html |
null |
Esophageal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of esophageal cancer. |
|
|
CLICK HERE |
| 1527 |
National Cancer Institute |
Html |
en |
Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of ovarian germ cell tumors. |
| cancer treatment | 0.301769 |
| cancer spreads | 0.255348 |
| malignant tumor cells | 0.277558 |
| body | 0.299082 |
| germ cell tumor | 0.800721 |
| chemotherapy | 0.280839 |
| PDQ cancer information | 0.300273 |
| Recurrent ovarian germ | 0.277404 |
| clinical trial search | 0.309632 |
| clinical trials | 0.590656 |
| cancer information summary | 0.281932 |
| clinical trial | 0.395991 |
| ovarian cancer | 0.264692 |
| patients | 0.271425 |
| total abdominal hysterectomy | 0.337207 |
| primary treatment | 0.256866 |
| treatment clinical trial | 0.254498 |
| NCI PDQ cancer | 0.256529 |
| Treatment Option Overview | 0.259623 |
| surgical procedure | 0.271995 |
| radiation therapy | 0.310569 |
| Treatment Editorial Board | 0.252931 |
| General information | 0.260406 |
| Serum tumor marker | 0.253975 |
|
| general cancer information | 0.252204 |
| treatment | 0.470981 |
| ovarian germ cell | 0.990461 |
| abdomen | 0.27139 |
| Peritoneal Cancer Treatment | 0.272441 |
| NCI-supported cancer | 0.272026 |
| cancer cells | 0.336912 |
| Cancer Information Service | 0.252497 |
| treatment clinical trials | 0.274003 |
| National Cancer Institute | 0.311767 |
| Primary Peritoneal Cancer | 0.275614 |
| tumor cells | 0.338991 |
| new treatment | 0.324139 |
| diagnose ovarian germ | 0.30268 |
| combination chemotherapy | 0.271369 |
| primary tumor | 0.253062 |
| metastatic tumor | 0.262931 |
| germ cell tumors | 0.577174 |
| common ovarian germ | 0.287657 |
| cancer clinical trials | 0.319376 |
| stage | 0.300535 |
| fallopian tubes | 0.264303 |
| cancer | 0.662842 |
| information | 0.326655 |
|
CLICK HERE |
| 1614 |
National Cancer Institute |
Html |
en |
Small Intestine Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of small intestine cancer. |
| treatment | 0.474663 |
| cancer treatment | 0.28121 |
| general information | 0.207525 |
| biologic therapy | 0.208552 |
| new cancer treatments | 0.211372 |
| NCI-supported cancer | 0.201612 |
| cancer cells | 0.363757 |
| small intestine leiomyosarcoma | 0.321766 |
| body | 0.259153 |
| Cancer Information Service | 0.211251 |
| PDQ cancer information | 0.323637 |
| clinical trial search | 0.240948 |
| intestine cancer spreads | 0.326211 |
| treatment clinical trials | 0.247389 |
| National Cancer Institute | 0.281738 |
| clinical trials | 0.768713 |
| small bowel | 0.209407 |
| cancer information summary | 0.278324 |
| clinical trial | 0.582681 |
|
| new treatment | 0.286343 |
| small intestine adenocarcinoma | 0.324343 |
| External radiation therapy | 0.208562 |
| patients | 0.225884 |
| Blood. The cancer | 0.205393 |
| large intestine | 0.315511 |
| treatment clinical trial | 0.212129 |
| NCI PDQ cancer | 0.228818 |
| cancer research process | 0.201049 |
| new anticancer drugs | 0.248329 |
| cancer clinical trials | 0.271351 |
| lymph nodes | 0.209989 |
| tumor | 0.247188 |
| radiation therapy | 0.498101 |
| Treatment Editorial Board | 0.224109 |
| cancer information summaries | 0.209407 |
| small intestine cancer | 0.951217 |
| comprehensive cancer information | 0.20938 |
| standard treatment | 0.222923 |
|
CLICK HERE |
| 1791 |
National Cancer Institute |
Html |
es |
Fatiga (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la fatiga, una afección caracterizada por extremo cansancio e incapacidad para funcionar por la falta de energía, que a menudo se observa como una complicación del cáncer y su tratamiento. |
| siguientes procedimientos | 0.385633 |
| anemia.Los análisis | 0.341771 |
| siguientes elementos | 0.380985 |
| descanso ayuda | 0.330891 |
| suficientes glóbulos | 0.429586 |
| siguientes hábitos | 0.360426 |
| fatiga mejora | 0.961013 |
| siguientes razones | 0.406276 |
| Mayor sentimiento | 0.336513 |
| causa anemia | 0.447908 |
| Más capacidad | 0.391264 |
| siguientes beneficios | 0.36204 |
| perÃodo intermedio | 0.361444 |
| terapia ayuda | 0.331417 |
| largo plazo | 0.508126 |
| menor cantidad | 0.379836 |
| suficiente oxÃgeno | 0.364828 |
| horarios regulares | 0.332634 |
| siguientes sÃntomas | 0.40531 |
| National Cancer Institute | 0.337934 |
| siguientes riesgos | 0.339715 |
| Mejor calidad | 0.332342 |
|
| paciente formas | 0.386322 |
| Terapia respiratoria | 0.332012 |
| vitamina b12 | 0.347342 |
| Instituto Nacional | 0.366294 |
| insuficiente cantidad | 0.340569 |
| siguientes problemas | 0.399021 |
| suficientes calorÃas | 0.375086 |
| Insuficiente apoyo | 0.328686 |
| siguientes factores | 0.398895 |
| Physician Data Query | 0.439181 |
| suficientes alimentos | 0.42156 |
| mayores probabilidades | 0.359824 |
| PDQ Fatiga | 0.692467 |
| Mejor apetito | 0.341698 |
| PDQ Trastornos | 0.417003 |
| posibles causas | 0.332899 |
| siguientes medicamentos | 0.4009 |
| general aumenta | 0.350637 |
| desesperanza frente | 0.332953 |
| menudo causa sÃntomas | 0.432855 |
| paciente preste atención | 0.49209 |
|
CLICK HERE |
| 1824 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer epitelial de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer epitelial de ovario, de trompas de Falopio y primario de peritoneo. |
| Obstet Gynecol | 0.328674 |
| adjuvant chemotherapy | 0.316668 |
| chemotherapy in ovarian | 0.322043 |
| prognostic factors | 0.308986 |
| pacientes portadores | 0.306542 |
| crecimiento infiltrante destructor | 0.31512 |
| American Cancer Society | 0.31686 |
| Breast Cancer Linkage | 0.317976 |
| Mol Cancer Ther | 0.309108 |
| estadio temprano cirugÃa | 0.310703 |
| Ovarian Cancer Registry | 0.325508 |
| Cancer Res | 0.30945 |
| Cancer Linkage Consortium | 0.317364 |
| ovarian cancer | 0.973902 |
| randomized trial | 0.311991 |
| FIGOa Estadio Definición | 0.307321 |
| ovarian carcinoma | 0.378303 |
| adjuvant chemotherapy in | 0.315561 |
| Natl Cancer Inst | 0.350243 |
| International Collaborative Ovarian | 0.315389 |
| Gynecologic Oncology Group | 0.347704 |
| Collaborative Ovarian Neoplasm | 0.316238 |
| Radner Familial Ovarian | 0.312567 |
| Gynecol Oncol | 0.326661 |
| patients with | 0.315269 |
|
| Metástasis peritoneales macroscópicas | 0.307056 |
| estadio iv | 0.341957 |
| estadio ii | 0.434604 |
| peritoneo estadio opciones | 0.310058 |
| Cancer Facts | 0.309636 |
| estadio ic | 0.320607 |
| estadio ib | 0.307072 |
| estadio ia | 0.317155 |
| Ovarian carcinoma diagnosis | 0.308469 |
| Oncology Group study | 0.306421 |
| Young RC | 0.307696 |
| familial ovarian cancer | 0.336296 |
| Brady MF | 0.306168 |
| estadio iia | 0.314327 |
| treated with cisplatin-based | 0.308377 |
| Clin Oncol | 0.327391 |
| Ovarian Neoplasm | 0.324824 |
| breast cancer | 0.321408 |
| in ovarian | 0.344499 |
| in ovarian neoplasm | 0.319834 |
| quimioterapia adyuvante versus | 0.306417 |
| estadio iii | 0.330381 |
| with cisplatin-based chemotherapy | 0.310441 |
| treated with | 0.312964 |
|
CLICK HERE |
| 1839 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores del sistema nervioso central en adultos (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores del sistema nervioso central en adultos. |
| carmustina versus | 0.548633 |
| malignant glioma | 0.86408 |
| WB Saunders Co | 0.553184 |
| American Cancer Society | 0.574098 |
| sumario tratamiento | 0.554962 |
| cuáles pacientes | 0.551482 |
| primary gliomas located | 0.577278 |
| idh1 mutation | 0.550619 |
| IDH2 mutations | 0.547874 |
| Radiation Therapy Oncology | 0.556783 |
| Radiat Oncol Biol | 0.675252 |
| central nervous system | 0.6889 |
| patients with | 0.664355 |
| Medical Research Council | 0.587686 |
| Brain Tumor Research | 0.559245 |
| Acta Neuropathol | 0.563339 |
| cerebral low-grade glioma | 0.542243 |
| diagnosed malignant glioma | 0.650146 |
| who classification | 0.562467 |
| Neuroimaging Clin | 0.54527 |
| chemotherapy with | 0.549687 |
| patients with glioblastoma | 0.549124 |
| tumor group study | 0.541376 |
| Organización Mundial | 0.549658 |
| Research Council Brain | 0.538383 |
|
| malignant glioma after | 0.544669 |
| Cancer Treatment | 0.573642 |
| Ohgaki H | 0.558609 |
| mortalidad posoperatoria | 0.540841 |
| patients with idh1 | 0.548495 |
| Bent MJ | 0.548927 |
| Therapy Oncology Group | 0.603297 |
| radioterapia posoperatoria | 0.576011 |
| BRAF V600E | 0.543097 |
| low-grade glioma | 0.559845 |
| primary malignant glioma | 0.547729 |
| conventional radiotherapy with | 0.572491 |
| National Cancer Institute | 0.578026 |
| radiotherapy with | 0.578973 |
| newly diagnosed malignant | 0.564043 |
| caracterÃsticas histológicas | 0.717766 |
| Radiation-induced malignant gliomas | 0.578762 |
| Clin Oncol | 0.624379 |
| sistema nervioso central | 0.979769 |
| brain tumor | 0.782394 |
| Oncol Biol Phys | 0.679866 |
| adult brain tumors | 0.545694 |
| Cancer Institute | 0.592793 |
| brain tumour | 0.610029 |
|
CLICK HERE |
| 1892 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de estómago (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago. |
| siguientes procedimientos | 0.623574 |
| estadio iv | 0.777016 |
| siguientes aspectos | 0.573343 |
| proteÃna vegf | 0.350025 |
| siguientes afecciones | 0.419234 |
| genes her2 | 0.549019 |
| exploraciones tep | 0.370808 |
| siguientes tipos | 0.374337 |
| cuerpo llamada | 0.407415 |
| rayos x | 0.496347 |
| estadio ib | 0.603838 |
| estadio ia | 0.601417 |
| enlace drugs approved | 0.548214 |
| escáner tep | 0.371104 |
| ondas sonoras | 0.369553 |
| estómago her2 | 0.993806 |
| proteÃna her2 | 0.939635 |
|
| siguientes sÃntomas | 0.405764 |
| National Cancer Institute | 0.33929 |
| siguientes riesgos | 0.335926 |
| Instituto Nacional | 0.373632 |
| PDQ Tratamiento | 0.63434 |
| estadio iiia | 0.59215 |
| estadio iiic | 0.584608 |
| estadio iiib | 0.586796 |
| estadio iia | 0.603101 |
| estadio iib | 0.602062 |
| partes distantes | 0.357123 |
| Physician Data Query | 0.452253 |
| antÃgeno carcinoembrionario | 0.374755 |
| Prueba ACE | 0.36171 |
| siguientes sumarios | 0.457366 |
| siguientes pruebas | 0.405163 |
|
CLICK HERE |
| 1970 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de paratiroides (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de paratiroides. |
| glándula tiroides | 0.438865 |
| Más sed | 0.410088 |
| siguientes procedimientos | 0.457489 |
| contraste circula | 0.409886 |
| glándula hiperactiva | 0.421803 |
| vÃa oral | 0.406242 |
| rayos x | 0.425707 |
| pequeñas marcas | 0.406116 |
| National Cancer Institute | 0.40574 |
| siguientes riesgos | 0.40413 |
| endocrina múltiple tipo | 0.418977 |
| Instituto Nacional | 0.410629 |
| malla ayuda | 0.405988 |
|
| hormona paratiroidea | 0.66472 |
| PDQ Tratamiento | 0.41212 |
| cabo pruebas | 0.412201 |
| glándulas paratiroides | 0.84566 |
| cuál glándula paratiroides | 0.475528 |
| Physician Data Query | 0.422464 |
| glándula paratiroides | 0.975564 |
| glándula paratiroides hiperactiva | 0.533736 |
| HPT ayuda | 0.413459 |
| toma imágenes | 0.439925 |
| siguientes pruebas | 0.41438 |
| largo tiempo | 0.406983 |
| siguientes trastornos | 0.411735 |
|
CLICK HERE |
| 3439 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico). |
| Visuals Online | 0.546235 |
| PDQ Exámenes | 0.690831 |
| siguientes efectos | 0.595148 |
| Physician Data Query | 0.831228 |
| siguientes afecciones | 0.665794 |
| Estados Unidos | 0.968946 |
| siguientes personas | 0.608962 |
| rayos x | 0.591974 |
| prevención revisa | 0.557627 |
|
| América Central | 0.603242 |
| principal causa | 0.614774 |
| información ayuda | 0.567593 |
| National Cancer Institute | 0.581719 |
| siguientes riesgos | 0.571014 |
| siguientes sumarios | 0.754212 |
| vitamina b12 | 0.617718 |
| Instituto Nacional | 0.653888 |
|
CLICK HERE |
| 3568 |
National Cancer Institute |
Html |
en |
An Overview of NCI’s National Clinical Trials Network |
Information about the National Clinical Trial Network’s structure and a synopsis of how NCTN improves the speed and efficiency of cancer clinical trials. |
| clinical trials experts | 0.464501 |
| future clinical trials | 0.469163 |
| University Comprehensive Cancer | 0.556492 |
| new clinical trials | 0.515991 |
| University Cancer Center | 0.54987 |
| lung cancer | 0.503721 |
| Colorado Cancer Center | 0.501413 |
| National Clinical Trials | 0.541018 |
| Siteman Cancer Center | 0.555425 |
| clinical trials | 0.992586 |
| Laboratory Cancer Center | 0.490529 |
| Cancer Center | 0.943642 |
| University Medical Center | 0.534585 |
| Stephenson Cancer Center | 0.498802 |
| Michigan Comprehensive Cancer | 0.464216 |
| Collaborating Clinical Trials | 0.493315 |
| NCI Community Cancer | 0.50292 |
| precision medicine | 0.594538 |
| Canadian Network Group | 0.472202 |
| multi-site clinical trials | 0.481274 |
| NCTN group | 0.467958 |
| precision medicine trials | 0.572352 |
| Cancer Research Center | 0.514033 |
| Case Comprehensive Cancer | 0.469578 |
| NCTN trials | 0.551195 |
|
| network groups | 0.486781 |
| Lineberger Comprehensive Cancer | 0.520793 |
| NCI clinical trials | 0.553596 |
| Anderson Cancer Center | 0.500046 |
| Clinical Trials Quality | 0.474372 |
| Clinical Trials Network | 0.579967 |
| Farber/Harvard Cancer Center | 0.50471 |
| Carbone Cancer Center | 0.498624 |
| Davis Comprehensive Cancer | 0.464747 |
| Simmons Cancer Center | 0.49746 |
| Winship Cancer Institute | 0.520221 |
| new national clinical | 0.508498 |
| Cooperative Group program | 0.540619 |
| Yale Cancer Center | 0.49495 |
| Ohio State University | 0.480826 |
| Comprehensive Cancer Center | 0.860218 |
| Kimmel Comprehensive Cancer | 0.464896 |
| Chicago Comprehensive Cancer | 0.464567 |
| previous clinical trials | 0.494398 |
| Cancer Institute | 0.668695 |
| cancer clinical trials | 0.605684 |
| cell lung cancer | 0.474785 |
| Cotton Cancer Center | 0.50297 |
| Ingram Cancer Center | 0.497253 |
|
CLICK HERE |